CJC-1295 No DAC 5mg
Modified GRF(1-29) for Pulsatile GH Release Research
CJC-1295 No DAC (Mod GRF 1-29) is a GHRH analogue with a 30-minute half-life that produces physiological pulsatile GH pulses, ideal for researching natural GH secretion patterns when paired with Ipamorelin.
Modified GRF(1-29) for Pulsatile GH Release Research
Modified GHRH(1-29) with four amino acid substitutions for improved stability; no Drug Affinity Complex means it acts like native GHRH with a physiological pulse duration, preserving normal GH release patterns without continuous baseline elevation.
As one of the most studied compounds in the growth & body comp research space, CJC-1295 has attracted sustained scientific interest across Pulsatile GH research, GHRH receptor studies, GH axis protocols. Peer-reviewed evidence indicates that preferred pulsatile GHRH for combination protocols, which has positioned CJC-1295 as a reference standard for researchers exploring pulsatile gh research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
CJC-1295 Documented Benefits: 3 Documented Mechanisms
Pulsatile GH Release
Produces physiological GH pulses matching natural GHRH-driven secretion timing.
GHRH Receptor Activation
Directly stimulates pituitary GHRH receptors for GH synthesis and release.
Synergistic with Ipamorelin
Dual mechanism with Ipamorelin produces amplified GH release vs. either alone.
How CJC-1295 Works: Molecular Mechanism & Pathway
Modified GHRH(1-29) analogue activating pituitary GHRH-R to stimulate GH synthesis, producing a single physiological pulse matching the ~30-minute natural GHRH half-life.
The 3 primary research pathways identified for CJC-1295 — Pulsatile GH Release, GHRH Receptor Activation, Synergistic with Ipamorelin — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that same receptor as endogenous GHRH, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, CJC-1295's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
CJC-1295 is routinely studied alongside Ipamorelin and CJC-1295 in growth & body comp-focused compound panels. Researchers investigating pulsatile gh research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that standard for CJC/Ipa combination research has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All CJC-1295 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Preferred pulsatile GHRH for combination protocols
- Same receptor as endogenous GHRH
- Standard for CJC/Ipa combination research
Ideal For
- Pulsatile GH research
- GHRH receptor studies
- GH axis protocols
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on CJC-1295. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Preferred pulsatile GHRH for combination protocols
Same receptor as endogenous GHRH
Standard for CJC/Ipa combination research
Third-Party Verified Every Batch
Each vial of CJC-1295 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
